Cargando…
Editorial note: repurposing FDA approved drugs as FXR agonists: a structure based in silico pharmacological study
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400029/ https://www.ncbi.nlm.nih.gov/pubmed/35994294 http://dx.doi.org/10.1042/BSR-2021-2791_EDN |
Ejemplares similares
-
Repurposing FDA-approved drugs as FXR agonists: a structure based in silico pharmacological study
por: Jose, Sandra, et al.
Publicado: (2023) -
Repurposing of FDA-approved drugs against cancer – focus on metastasis
por: Ozsvári, Béla, et al.
Publicado: (2016) -
Repurposing of existing FDA approved drugs for Neprilysin inhibition: An in-silico study
por: Sankhe, Runali, et al.
Publicado: (2021) -
Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016) -
In Silico and In
Vitro Potential of FDA-Approved Drugs
for Antimalarial Drug Repurposing against Plasmodium Serine Hydroxymethyltransferases
por: Mee-udorn, Pitchayathida, et al.
Publicado: (2023)